[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arrowhead Pharma (ARWR)

Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,524,919
  • Shares Outstanding, K 140,857
  • Annual Sales, $ 829,450 K
  • Annual Income, $ -1,630 K
  • EBIT $ -222 M
  • EBITDA $ -204 M
  • 60-Month Beta 1.28
  • Price/Sales 13.76
  • Price/Cash Flow 685.26
  • Price/Book 19.13

Options Overview Details

View History
  • Implied Volatility 57.68% (+1.94%)
  • Historical Volatility 54.60%
  • IV Percentile 6%
  • IV Rank 20.53%
  • IV High 100.09% on 07/21/25
  • IV Low 46.72% on 07/07/25
  • Expected Move (DTE 27) 9.29 (11.35%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 5,743
  • Volume Avg (30-Day) 1,193
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 43,412
  • Open Int (30-Day) 37,877
  • Expected Range 72.53 to 91.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.16
  • Number of Estimates 7
  • High Estimate $-0.26
  • Low Estimate $-1.50
  • Prior Year $-1.26
  • Growth Rate Est. (year over year) +7.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
69.30 +18.07%
on 06/02/26
84.55 -3.23%
on 06/18/26
+7.87 (+10.64%)
since 05/18/26
3-Month
54.89 +49.06%
on 03/20/26
84.55 -3.23%
on 06/18/26
+25.11 (+44.28%)
since 03/18/26
52-Week
14.30 +472.16%
on 07/22/25
84.55 -3.23%
on 06/18/26
+66.20 (+423.82%)
since 06/18/25

Most Recent Stories

More News
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that...

ARWR : 81.82 (+0.96%)
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James...

ARWR : 81.82 (+0.96%)
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2026 Jefferies Global Healthcare Conference –...

ARWR : 81.82 (+0.96%)
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

- Targeting Activin E may represent a novel therapeutic strategy for metabolic dysfunction-associated steatohepatitis (MASH) and obesity‑related metabolic dysfunction - ARO-INHBE produced meaningful...

ARWR : 81.82 (+0.96%)
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

- New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment - Case report suggests that preconception exposure...

ARWR : 81.82 (+0.96%)
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe...

ARWR : 81.82 (+0.96%)
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a presentation...

ARWR : 81.82 (+0.96%)
Arrowhead Pharmaceuticals Q2 Earnings Call Highlights

Arrowhead Pharmaceuticals (NASDAQ:ARWR) highlighted continued commercial traction for REDEMPLO and outlined multiple anticipated clinical catalysts in the second half of 2026 as the company reported fiscal...

ARWR : 81.82 (+0.96%)
Arrowhead Research: Fiscal Q2 Earnings Snapshot

Arrowhead Research: Fiscal Q2 Earnings Snapshot

ARWR : 81.82 (+0.96%)
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

- Conference Call and Webcast Today, May 7, 2026, at 4:30 p.m. ET

ARWR : 81.82 (+0.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes....

See More

Key Turning Points

3rd Resistance Point 89.06
2nd Resistance Point 86.80
1st Resistance Point 84.31
Last Price 81.82
1st Support Level 79.56
2nd Support Level 77.31
3rd Support Level 74.82

See More

52-Week High 84.55
Last Price 81.82
Fibonacci 61.8% 57.71
Fibonacci 50% 49.42
Fibonacci 38.2% 41.14
52-Week Low 14.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.